switching from glp 1 to tirzepatide Impact of CVS GLP-1 formulary change on prescribing Switching between GLP‐1 receptor agonists

In the case of MET-097i, it is a GLP-1 RA analog that has an extended half-life of ~15-16 days, which is many fold that of native GLP-1 peptide and more than 2x the half-life of semaglutide (GLP-1 RA)

Some users report new-onset insomnia, low mood, or sleep-onset anxiety, especially when food becomes emotionally charged

Danuglipron had once been considered a potential competitor to orforglipron

The C18 fatty diacid side chain must be synthesized separately and then chemically conjugated to a specific lysine residue on the peptide backbone through a glutamic acid linker

Patients who view GLP-1s as eliminating the need for dietary changes and exercise set themselves up for disappointment and potential health setbacks